CVS Health Corporation $CVS Shares Sold by Sheets Smith Wealth Management

Sheets Smith Wealth Management lowered its holdings in CVS Health Corporation (NYSE:CVS) by 46.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,211 shares of the pharmacy operator’s stock after selling 7,845 shares during the period. Sheets Smith Wealth Management’s holdings in CVS Health were worth $662,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd increased its position in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. acquired a new position in CVS Health during the 4th quarter worth $26,000. Sankala Group LLC purchased a new stake in CVS Health during the 4th quarter worth about $28,000. Mcguire Capital Advisors Inc. acquired a new stake in CVS Health in the 4th quarter valued at about $28,000. Finally, Ares Financial Consulting LLC purchased a new position in shares of CVS Health in the 4th quarter valued at about $29,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

Shares of CVS Health stock opened at $98.26 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $102.77. The firm’s 50 day moving average is $89.31 and its two-hundred day moving average is $81.50. The firm has a market capitalization of $125.38 billion, a P/E ratio of 43.29, a P/E/G ratio of 0.96 and a beta of 0.62.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the previous year, the firm earned $2.25 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Argus raised their target price on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Truist Financial boosted their price target on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft raised their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. TD Cowen boosted their target price on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Morgan Stanley increased their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.